From Innovation to Intervention
RadioMedix (radiomedix.com) scores 68 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 18th percentile of 18837 Healthcare brands.
RadioMedix is a clinical-stage biotechnology company headquartered in Houston, United States, focused on nuclear medicine. The company develops novel radiopharmaceuticals intended to advance both the diagnosis and treatment of cancer. Its stated mission is to pioneer innovation in the nuclear medicine field, moving beyond conventional approaches. RadioMedix's work spans research through clinical development stages, targeting oncologists, nuclear medicine physicians, healthcare institutions, and cancer patients who require advanced radiopharmaceutical diagnostic and therapeutic solutions.
| Brand Name | RadioMedix |
|---|---|
| Domain | radiomedix.com |
| Industry | Healthcare |
| Headquarters | Houston |
| Main Competitors | Lantheus Holdings (80/100), Curium Pharma (79/100), Telix Pharmaceuticals (75/100), Novartis (Advanced Accelerator Applications) (75/100), Clarity Pharmaceuticals (75/100), POINT Biopharma (70/100), Fusion Pharmaceuticals (76/100) |
Moz Domain Authority 30/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To pioneer the nuclear medicine landscape by developing innovative radiopharmaceuticals that transform cancer diagnosis and treatment." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on YouTube, X (Twitter), LinkedIn, Instagram, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
RadioMedix's main competitors in Healthcare: Lantheus Holdings (80/100), Curium Pharma (79/100), Telix Pharmaceuticals (75/100), Novartis (Advanced Accelerator Applications) (75/100), Clarity Pharmaceuticals (75/100).
Sources: Brand Analyzer scan
RadioMedix has limited AI-search visibility, scoring 25/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 15, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: RadioMedix official site
RadioMedix is headquartered in Houston. RadioMedix operates in the Healthcare category.
Sources: Wikidata
RadioMedix scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: RadioMedix official site
RadioMedix is a clinical-stage biotechnology company based in Houston, United States, that operates in the nuclear medicine sector. It focuses on developing novel radiopharmaceuticals designed to improve cancer diagnosis and treatment, positioning itself as a pioneer in advancing beyond traditional nuclear medicine approaches.
Sources: RadioMedix official site
RadioMedix develops innovative radiopharmaceuticals aimed at transforming cancer diagnosis and treatment. As a clinical-stage biotech, its work spans research and development through clinical intervention, creating radiopharmaceutical solutions intended for use by oncologists, nuclear medicine physicians, and healthcare institutions in managing cancer care.
Sources: RadioMedix official site
RadioMedix can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: RadioMedix official site
RadioMedix's radiopharmaceutical solutions are intended for use by oncologists, nuclear medicine physicians, healthcare institutions, and cancer patients who require advanced diagnostic and therapeutic options in cancer care.
Sources: RadioMedix official site
RadioMedix scores 25/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
RadioMedix has a weak AI-visibility profile at 25/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is trust (15/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 30/100 and thin schema.org structured data.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to RadioMedix: Radia Smart (68/100), Gateshead Health NHS Foundation Trust (68/100), RadMD (68/100), Randy's Mobility (68/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.